Investigating new treatments for ovarian cancer
Official title: The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-10931353 · Data updated 2026-11-12
This study is exploring new treatments for ovarian cancer that can work better for patients who haven't responded well to standard therapies, and it's designed for all women facing this challenge, especially those from different backgrounds.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,197,314 |
| NIH project number | 5P50CA281701-02 |
| Project ID | NIH-10931353 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with ovarian cancer, particularly those who have not responded well to standard treatments.
✕Less likely to help
Patients with non-ovarian cancers or those who are not currently undergoing treatment for ovarian cancer may not benefit from this research.
What this research studies
This research focuses on developing and testing innovative therapies for ovarian cancer, particularly those that can overcome resistance to existing treatments like chemotherapy and targeted therapies. The team at MD Anderson Cancer Center is working on strategies involving anti-angiogenic agents and immune checkpoint inhibitors, aiming to improve patient outcomes. They have a strong commitment to including diverse patient populations in their research, ensuring that findings are applicable to a wide range of individuals affected by ovarian cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer patients, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in similar therapeutic approaches for ovarian cancer, indicating a potential for significant advancements in treatment.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.